Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushenyijing is a traditional Chinese medicine (TCM) formulation, most commonly available as "Bushenyijing granules." It is used in China as an adjunctive therapy for cognitive impairment and neurodegenerative diseases such as Alzheimer's disease. The formula is based on TCM principles of "tonifying the kidney and replenishing essence," which are believed to support brain health and cognitive function. While the precise herbal composition may vary by manufacturer, it typically contains a combination of herbs aimed at improving memory, protecting neurons, reducing oxidative stress, and modulating inflammation. Clinical trials in China have investigated its use alone or in combination with other agents (e.g., calcium carbonate D3 tablets) for mild cognitive impairment and Alzheimer's disease[1][4][7]. The mechanism of action is multi-targeted according to TCM theory; specific molecular targets are not well defined in Western pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushenyijing.